Where will we open tomorrow?
15:31 ET Tomorrow's's Top Plays: Nymox Pharmaceutical Corp (NYMXF 10 1/4 +4 1/8) and Astea International (ATEA 4 3/32 +1 21/32) are two standout plays for tomorrow. Particularly think that NYMXF will have room to move, because of the media attention its Alzheimer's study will attract
_____________________________________________________
Company announced today that it may have found a major cause of Alzheimer's disease. Nymox's research team has discovered a new human brain entity called the "spheron" which they say satisfies 20 criteria of validity as a causal entity for Alzheimer's disease. The company, which has patents on the spherons, their use in diagnostics and therapeutics, as well as the spheron based new chemical entities, has several new drug candidates in development based on the spherons, treatments which may eventually be capable of slowing or stopping the disease. Nymox noted that the spheron based Nymox Alzheimer candidate drugs show positive effects in the test tube and in animals, with no toxicity thus far, but have not been tested in humans. While volume has not been exceptional at less than 600,000, this news is more than likely to get picked up by the national media tonight. In trader's terms, that probably means a pop at the open tomorrow. Hence, a purchase immediately before the close might be good for 10%-15% tomorrow. Of course, this is not a promise, but experience suggests that unless the market looks poor in pre-market tomorrow, the stock will move higher in early trading. Who knows, maybe CNBC will announce that the CEO is appearing in the morning -- that would really put some fire under the stock. Unfortunately, Joe Kernen isn't there today to pump the shares. If he were, NYMXF would be an automatic purchase at this level for a ride to $11 by the end of the day. |
